Sarah M McLeod

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 14

Top Topics

Acinetobacter Baumannii

Quality Control

Top Venues

Antimicrobial agents and chemotherapy

Future microbiology

Open forum infectious diseases

Journal of clinical microbiology

This page only lists publications with an associated author ORCID identifier.

Publications

Alita A Miller, Samir H Moussa, Sarah M McLeod
Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK). Antimicrobial agents and chemotherapy 68 (5) (2024)
Sarah M McLeod, Alita A Miller, Khurram Rana, David Altarac, Samir H Moussa, Adam B Shapiro
Clinical Outcomes for Patients With Monomicrobial vs Polymicrobial Acinetobacter baumannii-calcoaceticus Complex Infections Treated With Sulbactam-Durlobactam or Colistin: A Subset Analysis From a Phase 3 Clinical Trial. Open forum infectious diseases 11 (4) (2024)
Sarah M McLeod, Alita A Miller, Khurram Rana, David Altarac, Samir H Moussa, Adam B Shapiro
Clinical Outcomes for Patients With Monomicrobial vs Polymicrobial Acinetobacter baumannii-calcoaceticus Complex Infections Treated With Sulbactam-Durlobactam or Colistin: A Subset Analysis From a Phase 3 Clinical Trial. Open forum infectious diseases 11 (4) (2024)
Alita A Miller, Samir H Moussa, Sarah M McLeod
Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK). Antimicrobial agents and chemotherapy (2024)
Alita A Miller, Samir H Moussa, Sarah M McLeod
Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK). Antimicrobial agents and chemotherapy 68 (5) (2024)
Alita A Miller, Samir H Moussa, Sarah M McLeod
Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK). Antimicrobial agents and chemotherapy 68 (5) (2024)
Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, John P Mills, Keith S Kaye
Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii . Future microbiology 19 (7) (2024)
Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, John P Mills, Keith S Kaye
Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii . Future microbiology 19 (7) (2024)
Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, John P Mills, Keith S Kaye
Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii . Future microbiology (2024)
Alita A Miller, Samir H Moussa, Sarah M McLeod
Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK). Antimicrobial agents and chemotherapy 68 (5) (2024)
Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, John P Mills, Keith S Kaye
Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii . Future microbiology 19 (7) (2024)
Sarah M McLeod, John P O'Donnell, Navaneeth Narayanan, John P Mills, Keith S Kaye
Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii . Future microbiology (2024)
Sarah M McLeod, Nicole M Carter, Michael D Huband, Maria M Traczewski, Patricia A Bradford, Alita A Miller
Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests. Journal of clinical microbiology (2023)
Samir H Moussa, Adam B Shapiro, Sarah M McLeod, Ramkumar Iyer, Nicole M Carter, Yu-Kuo Tsai, L Kristopher Siu, Alita A Miller
Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of Acinetobacter baumannii . Antimicrobial agents and chemotherapy (2023)